JP2012512257A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012512257A5 JP2012512257A5 JP2011542431A JP2011542431A JP2012512257A5 JP 2012512257 A5 JP2012512257 A5 JP 2012512257A5 JP 2011542431 A JP2011542431 A JP 2011542431A JP 2011542431 A JP2011542431 A JP 2011542431A JP 2012512257 A5 JP2012512257 A5 JP 2012512257A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- item
- polypeptide antigen
- polypeptide
- chlamydia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13826108P | 2008-12-17 | 2008-12-17 | |
| US61/138,261 | 2008-12-17 | ||
| PCT/US2009/068457 WO2010078027A1 (en) | 2008-12-17 | 2009-12-17 | Chlamydia antigens and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012512257A JP2012512257A (ja) | 2012-05-31 |
| JP2012512257A5 true JP2012512257A5 (enExample) | 2013-02-07 |
Family
ID=42310157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011542431A Pending JP2012512257A (ja) | 2008-12-17 | 2009-12-17 | クラミジア抗原およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110293664A1 (enExample) |
| EP (1) | EP2379106A4 (enExample) |
| JP (1) | JP2012512257A (enExample) |
| AU (1) | AU2009333159A1 (enExample) |
| CA (1) | CA2781805A1 (enExample) |
| WO (1) | WO2010078027A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020061848A1 (en) * | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
| EP1981905B1 (en) * | 2006-01-16 | 2016-08-31 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Chlamydia vaccine |
| AU2010249330B2 (en) | 2009-05-22 | 2015-11-05 | Genocea Biosciences Inc. | Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response |
| EP2550289A4 (en) | 2010-03-12 | 2013-11-27 | Childrens Medical Center | NEW IMMUNOGENES AND METHODS FOR IDENTIFICATION AND SCREENING THEREOF |
| CA2849391A1 (en) * | 2010-10-20 | 2012-04-26 | Genocea Biosciences, Inc. | Chlamydia antigens and uses thereof |
| AU2011336894B2 (en) | 2010-11-24 | 2016-11-17 | Genocea Biosciences, Inc. | Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response |
| AU2012340712B2 (en) * | 2011-11-23 | 2017-09-14 | Genocea Biosciences, Inc. | Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response |
| CA2900008C (en) | 2013-02-07 | 2025-10-07 | Children's Medical Center Corporation | PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE |
| JP2019537555A (ja) | 2016-09-28 | 2019-12-26 | ジェノセア バイオサイエンシーズ， インコーポレイテッド | ヘルペスを処置するための方法および組成物 |
| TW202019470A (zh) | 2018-09-12 | 2020-06-01 | 美商艾芬尼維克斯公司 | 多價肺炎球菌疫苗 |
| WO2023039223A1 (en) | 2021-09-09 | 2023-03-16 | Affinivax, Inc. | Multivalent pneumococcal vaccines |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1280619A (zh) * | 1997-11-28 | 2001-01-17 | 根瑟特公司 | 沙眼衣原体的基因组序列和多肽,其片段以及其用途,特别是用于诊断、预防和治疗感染 |
| US6822071B1 (en) * | 1998-11-12 | 2004-11-23 | The Regents Of The University Of California | Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease |
| AU1722300A (en) * | 1998-11-12 | 2000-05-29 | Regents Of The University Of California, The | Chlamydia pneumoniae genome sequence |
| DE60228758D1 (de) * | 2001-12-12 | 2008-10-16 | Novartis Vaccines & Diagnostic | Immunisierung gegen chlamydia tracheomatis |
| GB0203403D0 (en) * | 2002-02-13 | 2002-04-03 | Chiron Spa | Chlamydia cytotoxic-T cell epitopes |
| EP1812055A4 (en) * | 2004-11-11 | 2008-09-03 | Univ Queensland | ANTIGENS OF CHLAMYDIA AND APPLICATIONS OF SAID ANTIGENS |
-
2009
- 2009-12-17 WO PCT/US2009/068457 patent/WO2010078027A1/en not_active Ceased
- 2009-12-17 AU AU2009333159A patent/AU2009333159A1/en not_active Abandoned
- 2009-12-17 US US13/140,773 patent/US20110293664A1/en not_active Abandoned
- 2009-12-17 EP EP09836943A patent/EP2379106A4/en not_active Withdrawn
- 2009-12-17 CA CA2781805A patent/CA2781805A1/en not_active Abandoned
- 2009-12-17 JP JP2011542431A patent/JP2012512257A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012512257A5 (enExample) | ||
| Cunningham et al. | Vaccine development: From concept to early clinical testing | |
| Dziadek et al. | Toxoplasma gondii: the vaccine potential of three trivalent antigen-cocktails composed of recombinant ROP2, ROP4, GRA4 and SAG1 proteins against chronic toxoplasmosis in BALB/c mice | |
| JP2023162283A5 (enExample) | ||
| JP2013545448A5 (enExample) | ||
| RU2490024C2 (ru) | Расширение спектра т клеток для включения субдоминантных эпитопов путем вакцинации с антигенами, доставленными как белковые фрагменты или пептидные коктейли | |
| JP2012152228A (ja) | 髄膜炎／敗血症に関連する大腸菌由来のタンパク質および核酸 | |
| TW200722101A (en) | Novel composition | |
| JP2010500399A (ja) | 尿路病原性大腸菌由来の免疫原 | |
| Dey et al. | Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens | |
| JP2016106117A5 (enExample) | ||
| Das et al. | Salmonella Typhi outer membrane protein STIV is a potential candidate for vaccine development against typhoid and paratyphoid fever | |
| Ni et al. | Protection against scrub typhus by a plasmid vaccine encoding the 56-KD outer membrane protein antigen gene | |
| El-Malky et al. | Vaccination with Toxoplasma lysate antigen and CpG oligodeoxynucleotides: comparison of immune responses in intranasal versus intramuscular administrations | |
| Irache et al. | Poly (anhydride) nanoparticles as adjuvants for mucosal vaccination | |
| Allahyari et al. | Co-delivery of PLGA nanoparticles loaded with rSAG1 antigen and TLR ligands: An efficient vaccine against chronic toxoplasmosis | |
| WO2005042564A1 (en) | Flagellin fusion proteins as adjuvants or vaccines and methods of use | |
| Maraghi et al. | Evaluation of immunogenicity and protective effect of DNA vaccine encoding surface antigen1 (SAG1) of Toxoplasma gondii and TLR-5 ligand as a genetic adjuvant against acute toxoplasmosis in BALB/c mice | |
| Da Fonseca et al. | Induction of antibody and T-cell responses by immunization with ISCOMS containing the 38-kilodalton protein of Mycobacterium tuberculosis | |
| Batzloff et al. | Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease | |
| Carneiro et al. | Vaccine engineering & structural vaccinology | |
| US20040115210A1 (en) | Imunogenic complex comprising ribosomes | |
| Kano et al. | Induced immune response of DNA vaccine encoding an association MSP1a, MSP1b, and MSP5 antigens of Anaplasma marginale | |
| de la Maza et al. | Determination of the safety and efficacy of recombinant Chlamydia muridarum MOMP vaccines, formulated with CpG-1826 and 70%, 50%, 30% or 10% concentrations of montanide ISA-720 VG, to elicit protective immune responses against a C. muridarum respiratory challenge | |
| Gheibihayat et al. | Mechanisms and performances of adjuvants in vaccine immunogenicity |